drugset
drugset / Trial / NCT05360927

Safety and Tolerability of BDB-001 Injection in Healthy Subjects

NCT05360927 ↗

Phase 1 Completed 28 enrolled Staidson (Beijing) Biopharmaceuticals Co., Ltd Beijing Defengrei Biotechnology Co.,Ltd · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A clinical study to evaluate the safety,tolerability,PK and PD characteristics of BDB-001 Injection in healthy subjects.

Timeline

Start
2019-09-25
Primary completion
2020-12-25
Completion
2020-12-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Resiquimod Small molecule 0.3 mg/kg Intravenous
Subject Resiquimod Small molecule 1 mg/kg Intravenous
Subject Resiquimod Small molecule 3 mg/kg Intravenous
Subject Resiquimod Small molecule 8 mg/kg Intravenous
Subject Resiquimod Small molecule 16 mg/kg Intravenous
Subject Resiquimod Small molecule 20 mg/kg Intravenous

Indications

No indication recorded.